Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
Other Sizes |
|
Afamelanotide (Melanotan I; MT-I; CUV-1647; MBJ05; trade name Scenesse) is a synthetic peptide analog of α-melanocyte stimulating hormone (α-MSH), acting as a melanocortin receptor agonist and has been approved for use to prevent skin damage from the sun in people with erythropoietic protoporphyria in EU and USA. Skin becomes darker as a result (it produces more melanin and gets tan).
Targets |
MC1R
|
---|---|
References |
Molecular Formula |
C78H111N21O19
|
---|---|
Molecular Weight |
1646.84524
|
Exact Mass |
1645.84
|
Elemental Analysis |
C, 56.89; H, 6.79; N, 17.86; O, 18.46
|
CAS # |
75921-69-6
|
Related CAS # |
Melanotan I acetate; 1566590-77-9
|
Appearance |
Solid powder
|
SMILES |
CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
|
InChi Key |
UAHFGYDRQSXQEB-PWPYQVNISA-N
|
InChi Code |
InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,65-/m0/s1
|
Chemical Name |
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
|
Synonyms |
CUV-1647; CUV 1647; CUV1647; Afamelanotide; MBJ-05; MBJ 05; MBJ05; Melanotan I; MT-I; [Nle4,D-Phe7]-α-MSH
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O: ≥ 50 mg/mL (~30.4 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (60.72 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.6072 mL | 3.0361 mL | 6.0722 mL | |
5 mM | 0.1214 mL | 0.6072 mL | 1.2144 mL | |
10 mM | 0.0607 mL | 0.3036 mL | 0.6072 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05854784 | Active Recruiting |
Drug: Afamelanotide 16 MG | Variegate Porphyria | Clinuvel (UK) Ltd. | March 28, 2023 | Phase 2 |
NCT05159752 | Recruiting | Drug: Afamelanotide | Xeroderma Pigmentosum | Clinuvel Europe Limited | October 19, 2021 | Phase 2 |
NCT05210582 | Recruiting | Drug: Afamelanotide | Vitiligo | Clinuvel, Inc. | October 11, 2022 | Phase 2 |
NCT06109649 | Recruiting | Procedure: NB-UVB Light Drug: Afamelanotide and NB-UVB Light |
Vitiligo | Clinuvel, Inc. | October 11, 2023 | Phase 3 |
NCT05370235 | Recruiting | Drug: Afamelanotide | Xeroderma Pigmentosum | Clinuvel Europe Limited | March 28, 2022 | Phase 2 |